劲方医药-B(02595)今日盘中大幅上涨5.55%，引起了市场的高度关注。
消息面上，公司核心产品GFH375获得第二项突破性疗法认定，成为国内首个KRAS G12D抑制剂单药治疗方案被纳入胰腺癌突破性疗法认定名单，此前该产品已获得非小细胞肺癌（NSCLC）的突破性疗法认定。这一进展显著提振了市场对公司RAS靶点药物研发布局的信心。
此外，公司披露的年度报告显示，全年实现收入1.30亿元人民币，同比增长24.4%；研发投入达3.32亿元人民币，较上年进一步加码，资产负债表结构也得到显著改善。尽管归母净利润仍处于亏损状态，但核心管线的连续突破被视为公司长期价值的重要支撑。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.